School of Medicine, Universidad del Rosario, Bogotá, Colombia.
School of Medicine, Pontificia Universidad Javeriana, Bogotá, Colombia.
BMC Surg. 2022 Dec 12;22(1):424. doi: 10.1186/s12893-022-01839-x.
Chronic pancreatitis is an inflammatory disease characterized by irreversible morphological changes due to chronic pancreatic fibrosis. The treatment goals are to relieve pain, preserve function, and prevent further pathological consequences. Endoscopic treatment, surgery, or both are options for untreatable pain or suspected malignancy. Frey procedure is a reasonable surgical intervention because of its hybrid character, combining resection and drainage. Unfortunately, there is limited information about the outcomes of this procedure in Latin America, and few cases described in Colombia. This study aims to describe the experience of a pancreatic surgery reference center in the management of patients undergoing Frey's surgery for chronic pancreatitis.
A retrospective review of a prospectively collected database of patients who underwent a Frey procedure due to chronic pancreatitis between January 2014 to February 2022 in a hospital in Bogotá, Colombia, was made. A demographic, clinical, and postoperative outcome description was performed. Mann-Whitney Willcoxon test was performed between operative variables and long-term outcomes.
Eighteen patients met the inclusion criteria. 55.5% of patients were male. Chronic pancreatitis etiology in most cases (83.3% n = 15) was idiopathic. The median duration of symptoms and chronic pancreatitis diagnosis before surgery was 6.15 months (IQR 5;97). Overall morbidity was 38.88%. One patient died at 30 days of follow-up. The median follow-up time was 42.5 (IQR 19;65 months). The median pain reduction was 3 points according to the visual analog score. Six patients were diagnosed with malignant conditions after surgery (mean 27.8 ± 7.5 months). Wirsung's duct size was statistically related with malignancy presentation after Frey's procedure (Z = 2.54; P = 0.01).
According to our data, Frey's procedure remains safe and feasible, with acceptable outcomes in terms of pain relief and pancreatic function. The study confirms the importance of a longstanding follow-up due to an inherent risk of pancreatic malignancy. Our data suggest that pancreatic duct size could be related with the malignancy diagnosis after Frey's procedure; however, further prospective studies with a larger sample size would be helpful to confirm these results.
慢性胰腺炎是一种炎症性疾病,其特征为慢性胰腺纤维化导致不可逆转的形态学改变。治疗目标是缓解疼痛、保留功能并防止进一步的病理后果。对于无法治疗的疼痛或疑似恶性肿瘤,可选择内镜治疗、手术或两者兼施。 Frey 手术是一种合理的手术干预,因为它具有混合特征,结合了切除和引流。不幸的是,关于该手术在拉丁美洲的结果的信息有限,哥伦比亚也仅有少数病例报道。本研究旨在描述一家胰腺外科参考中心在处理因慢性胰腺炎接受 Frey 手术的患者方面的经验。
对 2014 年 1 月至 2022 年 2 月期间在哥伦比亚波哥大的一家医院因慢性胰腺炎接受 Frey 手术的患者前瞻性收集数据库进行回顾性分析。对患者的人口统计学、临床和术后结局进行描述。对手术变量和长期结局进行 Mann-Whitney Willcoxon 检验。
18 名患者符合纳入标准。55.5%的患者为男性。大多数病例(83.3%,n=15)的慢性胰腺炎病因是特发性的。手术前症状和慢性胰腺炎诊断的中位持续时间为 6.15 个月(IQR 5;97)。总体发病率为 38.88%。1 例患者在术后 30 天随访时死亡。中位随访时间为 42.5 个月(IQR 19;65 个月)。根据视觉模拟评分,疼痛缓解中位数为 3 分。6 名患者术后诊断出恶性疾病(平均 27.8±7.5 个月)。 Frey 手术后 Wirsung 导管大小与恶性表现呈统计学相关(Z=2.54;P=0.01)。
根据我们的数据,Frey 手术仍然是安全可行的,在缓解疼痛和保留胰腺功能方面具有可接受的结果。该研究证实了长期随访的重要性,因为存在胰腺恶性肿瘤的固有风险。我们的数据表明,胰腺导管大小可能与 Frey 手术后的恶性诊断有关;然而,需要进一步的前瞻性研究,以更大的样本量来证实这些结果。